Dongbao to acquire Ferring’s Malmö manufacturing operation

Dongbao to acquire Ferring’s Malmö manufacturing operation
17 November 2006 pulse

Dongbao to acquire Ferring’s Malmö manufacturing operation

Saint-Prex, Switzerland and Shanghai, China – 17 November, 2006 –

Ferring Pharmaceuticals and Shanghai Dongbao Biopharmaceutical Company announced today the signing of an agreement by which Dongbao Biopharmaceutical will purchase Ferring’s manufacturing operation at Malmö in Sweden.

Earlier this year, Ferring informed staff of its plan to cease manufacturing at Malmö by the end of March 2008. However, the acquisition by Dongbao Biopharmaceutical has secured the jobs of around 50 members of staff. The agreement will become effective on 1 January, 2007.

“From the very beginning, our aim has been to find a solution which would maintain the Malmö production site,” commented Ferring Pharmaceuticals Chief Operating Officer, Michel Pettigrew. “This agreement is a boost for the local community and has secured the long-term future of the factory for around 50 employees, whose experience will be invaluable to Dongbao Biopharmaceutical.”

“We see great potential for the manufacturing centre at Malmö”, added Dr George Li, President of Dongbao Biopharmaceutical. “The site is technically very developed and the current team, who will be an important part of our future business development, offer a lot of knowledge and competencies.”

About Dongbao Biopharmaceutical

Shanghai Dongbao Biopharmaceutical Co., Ltd. is part of the business operation of Dongbao Enterprise Group Co., Ltd., which is one of the leading biopharmaceutical groups in China. In recent years, Dongbao Group has successfully developed from a traditional pharmaceutical company into a high-tech biopharmaceutical company. As one of the most important divisions of Dongbao group, Shanghai Dongbao Biopharmaceutical Co., Ltd. is handling the group’s international development strategies.

For more information about Dongbao, please visit

About Ferring Pharmaceuticals

Ferring is a Swiss-based research driven, speciality biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, gynaecology, fertility and urology. In recent years Ferring has expanded beyond its traditional European base and now has offices in over 40 countries.

To learn more about Ferring or our products please visit

For more information, please contact

Michael George
Ferring Pharmaceuticals
+41 58 301 00 53

Dr. George Li
Shanghai Dongbao Pharmaceutical Co Ltd.
+86 21 639 10001

Press Kit
Press release in English View
Press release in Swedish View

This page is not intended for patients or for members of the general public. It is only intended to be used by healthcare professionals.


Cette page n'est pas destinée aux patients ou au grand public. Il est uniquement destiné à être utilisé par des professionnels de santé.


Ik bevestig dat ik een professionele zorgverlener ben of een zakelijke relatie heb met Ferring Pharmaceuticals


Ez az oldal nem betegeknek, vagy nagyközönségnek szól. Az oldalt kizárólag egészségügyi szakemberek használhatják.


Ta strona nie jest przeznaczona dla pacjentów ani dla ogółu odwiedzających. Ta strona stworzona jest dla pracowników sektora ochrony zdrowia.


Эта страница не предназначена для пациентов или для широкой публики. Она предназначена только для медицинских работников.